Abstract |
A 51-year-old postmenopausal woman was referred to our hospital for treatment of ER-positive recurrent breast cancer. The patient had lung and pleural metastases with pleural effusion from breast cancer. She was treated with anastrozole, a 3rd-generation aromatiase inhibitor. The efficacy of the treatment was definite: the multiple metastatic lung lesions showed a partial response after 5 months' treatment, and reached a complete response after 14 months' treatment. The patient experienced no adverse effects with this therapy. Anastrozole therapy is a useful treatment for postmenopausal woman with ER-positive recurrent breast cancer.
|
Authors | Shuichiro Maruyama, Maiko Ito, Yutaka Hirano, Toshiro Shimo, Shinsuke Hashida, Korechika Iga, Michio Inukai, Yoshiaki Kanaya, Nobuji Yokoyama |
Journal | Gan to kagaku ryoho. Cancer & chemotherapy
(Gan To Kagaku Ryoho)
Vol. 35
Issue 10
Pg. 1787-9
(Oct 2008)
ISSN: 0385-0684 [Print] Japan |
PMID | 18931590
(Publication Type: Case Reports, Journal Article)
|
Chemical References |
- Biomarkers, Tumor
- Nitriles
- Triazoles
- Anastrozole
|
Topics |
- Anastrozole
- Biomarkers, Tumor
(blood)
- Breast Neoplasms
(blood, drug therapy, pathology, surgery)
- Female
- Humans
- Lung Neoplasms
(blood, diagnostic imaging, drug therapy, secondary)
- Middle Aged
- Neoplasm Recurrence, Local
(blood, diagnostic imaging, drug therapy)
- Nitriles
(therapeutic use)
- Radiography
- Triazoles
(therapeutic use)
|